Table 1.
Study treatment groups, their respective conjugate vaccine formulation, AI equivalent dose and experimental regime.
| Days | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days Injection | Blood sample | Challenge AI/AII | ||||||||||||
| Study | PMD code | Formulation | AI dose (µg) | 0 | 21 | 42 | 0 | 7 | 14 | 21 | 28 | 42 | 49 | |
| A | None | Saline control | 0 | • | • | • | • | • | • | 63 | ||||
| PMD2850 | AI–TT, Al(OH)3 | 25 | • | • | • | • | • | • | 63 | |||||
| PMD3117 | AI–KLH, Al(OH)3 | 10, 50 | • | • | • | • | • | • | 63 | |||||
| B | None | Saline control | 0 | • | • | • | • | • | • | |||||
| PMD2850 | AI–TT, Al(OH)3 | 10, 20, 50, 100 | • | • | • | • | • | • | ||||||
| C | None | Saline control | 0 | • | • | • | • | • | • | |||||
| PMD3117 | AI–KLH, Al(OH)3 | 25, 50, 100 | • | • | • | • | • | • | • | |||||
| D | None | Al(OH)3 | 0 | • | • | • | • | • | − 1 & 49 | |||||
| PMD3117 | AI–KLH, Al(OH)3 | 50 | • | • | • | • | • | − 1 & 49 | ||||||
AI/AII, Angiotensin I or II hormone; AI, peptide analogue of AI; PMD, Protherics plc.; TT, tetanus toxoid peptide carrier protein; Al(OH)3, Alhydrogel® gel adjuvant; KLH, keyhole limpet haemocyanin peptide carrier protein; •, treatment.